Viral suppression in Cerebrospinal Fluid in HIV-1 infected patients receiving Ritonavir-boosted Atazanavir plus lamivudine dual theraphy. SCALA study

Trial Profile

Viral suppression in Cerebrospinal Fluid in HIV-1 infected patients receiving Ritonavir-boosted Atazanavir plus lamivudine dual theraphy. SCALA study

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 10 Jul 2014

At a glance

  • Drugs Atazanavir (Primary) ; Lamivudine (Primary) ; Ritonavir
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Acronyms SCALA
  • Most Recent Events

    • 10 Jul 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top